Rituximab following natalizumab withdrawal in relapsing remitting multiple sclerosis

被引：0
|
作者：
Beaber, B. E. [1 ]
Mallari, G. [1 ]
Le, D. [1 ]
Langer-Gould, A. M. [1 ,2 ]
机构：
[1] So Calif Permanente Med Grp, Los Angeles Med Ctr, Neurol, Los Angeles, CA USA
[2] Kaiser Permanente So Calif, Res & Evaluat, Pasadena, CA 91101 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P283
引用
收藏
页码：193 / 193
页数：1
相关论文
共 50 条
  • [31] Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
    Malin Boremalm
    Peter Sundström
    Jonatan Salzer
    [J]. Journal of Neurology, 2021, 268 : 2161 - 2168
  • [32] Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, Carmen
    Gascon, F.
    Perez-Miralles, Francisco
    Dominguez, J. A.
    Gil-Perotin, S.
    Casanova, B.
    [J]. JOURNAL OF NEUROLOGY, 2019, 266 (03) : 726 - 734
  • [33] Medication withdrawal in relapsing-remitting multiple sclerosis: why not?
    Modolo, G. P.
    do Olival, G. S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (04) : 679 - 680
  • [34] Disease activity following fingolimod withdrawal in relapsing remitting multiple sclerosis: a monocentric Italian study
    Esposito, F.
    Ferre, L.
    Clarelli, F.
    Mogavero, A.
    Romeo, M.
    Colombo, B.
    Moiola, L.
    Martinelli, V.
    Leocani, L.
    Filippi, M.
    Comi, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 166 - 166
  • [35] Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis
    Paul L. McCormack
    [J]. Drugs, 2013, 73 : 1463 - 1481
  • [36] Course of relapsing-remitting multiple sclerosis before, during and after natalizumab
    Kaufman, Michael D.
    Lee, R.
    Norton, H. J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (04) : 490 - 494
  • [37] Natalizumab arrests cortical atrophy progression in relapsing-remitting multiple sclerosis
    Rinaldi, F.
    Calabrese, M.
    Mattisi, I.
    Seppi, D.
    Puthenparampil, M.
    Perini, P.
    Gallo, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S195 - S196
  • [38] Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
    Stephanie R. Earnshaw
    Jonathan Graham
    MerriKay Oleen-Burkey
    Jane Castelli-Haley
    Kenneth Johnson
    [J]. Applied Health Economics and Health Policy, 2009, 7 (2) : 91 - 108
  • [39] A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
    Trojano, Maria
    Ramio-Torrenta, Lluis
    Grimaldi, Luigi M. E.
    Lubetzki, Catherine
    Schippling, Sven
    Evans, Karleyton C.
    Ren, Zheng
    Muralidharan, Kumar Kandadi
    Licata, Stephanie
    Gafson, Arie R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2240 - 2253
  • [40] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
12345